Serotonin 1D Receptor Agonist Market Size, Share, Growth, Trends, and Global Industry Analysis: Competitive Landscape, Pipeline, and Market Size, Share, Growth, Trends, and Global Industry Analysis: Analysis 2024

5-hydroxytryptamine (serotonin) receptor 1D, also known as HTR1D, is a 5-HT receptor. 5-HT1D acts on the central nervous system and affects locomotion and anxiety. It also induces vasoconstriction in the brain. 5HT1D receptors are found at low levels in the basal ganglia (globus pallidus, substantia nigra, caudate putamen), the hippocampus, and in the cortex. The mechanism of action (MOA) of the Serotonin 1D Receptor Agonist is by 5-HT1B/1D receptors and includes vasoconstriction of painfully dilated cerebral blood vessels, inhibition of the release of vasoactive neuropeptides by trigeminal nerves, and inhibition of nociceptive neurotransmission. Serotonin 1D Receptor Agonists are used in the treatment of CNS disorders, headache, migraine disorders, neoplasm metastasis, reperfusion injury, cognition disorders, delirium, nausea, pelvic pain, wounds, injuries, acne vulgaris, arthralgia, etc.

Increased prevalence of migraine and brain disorders are the key drivers for the Serotonin 1D Receptor Agonist market. For instance, according to the World Health Organization 2023, it has been estimated that the prevalence among adults of current headache disorder (symptomatic at least once within the last year) is about 50%. The introduction of newer products by market players may look for opportunities that have a big impact on comprehensive research and development in Serotonin 1D Receptor Agonists. For instance, Allergan and AbbVie launched Botox (Onabotulinumtoxin A) for the treatment of chronic migraine. Moreover, to address the difficulties in therapy, numerous market participants are developing innovative compounds. For instance, Neurim’s Piromelatine (Neu P11) for the indication of Alzheimer's disease is under the various stages of clinical studies.

Serotonin 1D Receptor Agonist Market Key Developments:

• In January 2019, Upsher-Smith Laboratories received FDA approval for Tosymra (Sumatriptan) Nasal Spray for the treatment of acute migraine in adults.
• In July 2020, GSK, Allergan in global collaboration with AbbVie received FDA approval for the additional use of Botox (Onabotulinumtoxin A) for spasticity in pediatric patients 2 years of age and older, including those with lower limb spasticity caused by cerebral palsy.

Approved Drug Molecules and Brand Names for Serotonin 1D Receptor Agonist:

•  Botox (Onabotulinumtoxin A)
•  Tosymra (Sumatriptan) Nasal Spray
•  Onzetra Xsail (Sumatriptan Nasal Powder)
•  Relpax (Eletriptan Hydrobromide)
•  Maxalt (Rizatriptan Benzoate)
•  Imitrex (Sumatriptan)

Drugs under the Pipeline for Serotonin 1D Receptor Agonist:

• Piromelatine (Neu P11)
• Semprana (Dihydroergotamine Oral Inhalation)
• Dihydroergotamine Intranasal (STS101)
• ONZETRA Xsail (Sumatriptan Intranasal)
• Sumavel Dosepro (Sumatriptan Succinate Needle-Free Subcutaneous Injection)
• Meloxicam
• Zolmitriptan Intracutaneous Microneedle System (C213)
• NXN-188
• Trudhesa (Dihydroergotamine Mesylate Intranasal)
• ZEMBRACE Symtouch (Sumatriptan Succinate)
• Tosymra (Intranasal Sumatriptan)
• Zeneo Sumatriptan (Sumatriptan Needle-Free Injection)
• Promethazine/Sumatriptan (CL-H1T)
• Zolmitriptan Inhalational (CVT-427)
• Alsuma (Sumatriptan Succinate Subcutaneous Injection)
• Ergonex (Ergotamine/Caffeine)
• Omexa (Sumatriptan Transmucosal)
• Dihydroergotamine (PUR3100)
• Rizatriptan/Naproxen

Clinical Activity and Developments of Serotonin 1D Receptor Agonist:

Up until June 2023, there will be about 28 companies with over 35 compounds that focus on various forms of migraine and CNS disorders. For these molecules, more than 191 of clinical trials are being conducted and the majority are in phase-2 and phase-3 clinical trials by the players across the globe. For instance,

• In February 2020, NEURIM Pharmaceutical completed phase 2, a randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study of Piromelatine (Neu P11) in patients with mild dementia due to Alzheimer's disease.
• In June 2023, GSK completed phase 3, a Multicenter, Randomized, Evaluator-masked, Parallel-group, Non-treatment-controlled Study Followed by an Open-label Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus.